M. Wang

598 total citations
32 papers, 351 citations indexed

About

M. Wang is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, M. Wang has authored 32 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 14 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in M. Wang's work include Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CAR-T cell therapy research (6 papers). M. Wang is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (9 papers) and CAR-T cell therapy research (6 papers). M. Wang collaborates with scholars based in United States, China and Australia. M. Wang's co-authors include Sergio Giralt, Raymond Alexanian, Kay Delasalle, Beverly C. Handy, L. Zhang, Xiaohong Han, Qing Yi, Jorge Romaguera, Larry W. Kwak and Jian Yang and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

M. Wang

25 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Wang United States 8 191 176 151 116 81 32 351
Lixia Pei United States 10 176 0.9× 312 1.8× 180 1.2× 224 1.9× 144 1.8× 27 476
Atsushi Isoda Japan 10 73 0.4× 158 0.9× 96 0.6× 139 1.2× 42 0.5× 27 321
Fernando Escalante Spain 10 171 0.9× 120 0.7× 236 1.6× 41 0.4× 84 1.0× 36 325
Enrica Borsi Italy 12 243 1.3× 157 0.9× 239 1.6× 54 0.5× 34 0.4× 26 392
Yasuhito Suehara Japan 10 105 0.5× 75 0.4× 134 0.9× 100 0.9× 73 0.9× 34 278
Daisy Moreno United States 7 178 0.9× 61 0.3× 201 1.3× 70 0.6× 174 2.1× 9 430
Victor Priego United States 7 93 0.5× 74 0.4× 142 0.9× 69 0.6× 120 1.5× 21 330
Arthur I. Radin United States 6 126 0.7× 154 0.9× 58 0.4× 76 0.7× 44 0.5× 8 317
Bianca Schuhmacher Germany 6 81 0.4× 85 0.5× 117 0.8× 110 0.9× 116 1.4× 9 316
Marina Martello Italy 10 303 1.6× 218 1.2× 352 2.3× 42 0.4× 48 0.6× 30 472

Countries citing papers authored by M. Wang

Since Specialization
Citations

This map shows the geographic impact of M. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Wang more than expected).

Fields of papers citing papers by M. Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Wang. The network helps show where M. Wang may publish in the future.

Co-authorship network of co-authors of M. Wang

This figure shows the co-authorship network connecting the top 25 collaborators of M. Wang. A scholar is included among the top collaborators of M. Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Wang. M. Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cai, Jie, et al.. (2025). p16INK4a downregulation alleviates temporomandibular joint osteoarthritis combined with type 2 diabetes by driving M2 polarization. Biomedicine & Pharmacotherapy. 188. 118172–118172. 1 indexed citations
2.
Arena, Marika, et al.. (2025). ESG Rating Disagreement and Sustainability Reporting: The Role of Reporting Standards and Assurance Practices. Corporate Social Responsibility and Environmental Management. 32(4). 5446–5468. 1 indexed citations
3.
Yuan, Guang, et al.. (2025). Screening for resistance to Aspergillus flavus invasion and aflatoxin production in peanut. Genetic Resources and Crop Evolution. 72(6). 6581–6596. 1 indexed citations
4.
Wang, M., et al.. (2025). Cuproptosis-triggering nanomedicine boosts antitumor immunotherapy. Theranostics. 16(5). 2405–2446.
5.
6.
Wang, M., et al.. (2025). Angiogenesis-related gene signature for prognostic prediction and immune microenvironment characterization in diffuse large B-cell lymphoma. Clinical and Experimental Medicine. 25(1). 108–108. 1 indexed citations
7.
8.
Fan, Lixian, et al.. (2024). Fleet sustainability of the liner market—from the perspective of corporate social responsibility. Maritime Policy & Management. 52(2). 173–189. 1 indexed citations
9.
Song, Mei, Shuting Huang, Ziyi Zhao, et al.. (2024). UBR5 mediates colorectal cancer chemoresistance by attenuating ferroptosis via Lys 11 ubiquitin-dependent stabilization of Smad3-SLC7A11 signaling. Redox Biology. 76. 103349–103349. 10 indexed citations
10.
Wang, M., Gilles Salles, Anita Kumar, et al.. (2021). ROLE OF MAINTENANCE RITUXIMAB AFTER FIRST‐LINE BENDAMUSTINE + RITUXIMAB OR R‐CHOP IN PATIENTS WITH MANTLE CELL LYMPHOMA FROM A LARGE US REAL‐WORLD COHORT. Hematological Oncology. 39(S2). 2 indexed citations
11.
Kersten, Marie José, Nöel Milpied, Gregory A. Maglinte, et al.. (2020). PCN324 Patient Reported Outcomes Among Kte-X19 CAR T Treated Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL). Value in Health. 23. S479–S479. 1 indexed citations
12.
Wang, M., Lionel Karlin, Wojciech Jurczak, et al.. (2019). RESULTS FROM THE SAFETY RUN‐IN PERIOD OF THE SYMPATICO STUDY EVALUATING IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA. Hematological Oncology. 37(S2). 333–335. 3 indexed citations
13.
14.
Cheah, Chan Y., Dai Chihara, S. Horowitz, et al.. (2016). Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology. 27(7). 1317–1323. 21 indexed citations
15.
Wang, M., Frederick L. Locke, Tanya Siddiqi, et al.. (2016). ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL). Annals of Oncology. 27. vi326–vi326. 7 indexed citations
16.
Merriman, Kelly W., Heather Lin, M. Wang, et al.. (2014). The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. British Journal of Cancer. 111(3). 628–636. 61 indexed citations
17.
Wang, M., Kay Delasalle, Sergio Giralt, & Raymond Alexanian. (2010). Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD). Hematology. 15(2). 70–73. 11 indexed citations
18.
Wang, M., Lejia Sun, Jianfei Qian, et al.. (2009). Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 23(7). 1320–1328. 26 indexed citations
19.
Wang, M., Xiaohong Han, L. Zhang, et al.. (2007). Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 22(1). 179–185. 76 indexed citations
20.
Fayad, Luis, Sarah Temple, Barbara Pro, et al.. (2007). R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma (DLBCL) with aggressive features: M. D. Anderson experience in 40 patients. Journal of Clinical Oncology. 25(18_suppl). 8058–8058. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lixia Pei Breakdown of academic impact, for papers by Atsushi Isoda Breakdown of academic impact, for papers by Fernando Escalante Breakdown of academic impact, for papers by Enrica Borsi Breakdown of academic impact, for papers by Yasuhito Suehara Breakdown of academic impact, for papers by Daisy Moreno Breakdown of academic impact, for papers by Victor Priego Breakdown of academic impact, for papers by Arthur I. Radin Breakdown of academic impact, for papers by Bianca Schuhmacher Breakdown of academic impact, for papers by Marina Martello
Rankless by CCL
2026